|
"shan y s"的相關文件
顯示項目 36-45 / 95 (共10頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.;Tsai K.K.;Hsiao C.-F.;Yang S.-H.;Hsiao H.-H.;Shen W.-C.;Chiun Hsu;Lin Y.-L.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; Yang S.-H.; Hsiao H.-H.; Shen W.-C.; Chiun Hsu; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.;Chou W.-C.;Hsiao C.-F.;Jiang S.S.;Tsai H.-J.;Liu Y.-C.;Chiun Hsu;Shan Y.-S.;Hung Y.-P.;Hsich C.-H.;Chiu C.-H.;Liu T.-C.;Cho S.-F.;Liu T.-W.;Chao Y.; Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; Chiun Hsu; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.;Chen M.-H.;Yang S.-H.;Chiun Hsu;Yen C.-J.;Tsou H.-H.;Su Y.-Y.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Chen M.-H.; Yang S.-H.; Chiun Hsu; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:35Z |
Management of gastric cancer in Asia: Resource-stratified guidelines
|
Shen L.;Shan Y.-S.;Hu H.-M.;Price T.J.;Sirohi B.;Kun-Huei Yeh;Yang Y.-H.;Sano T.;Yang H.-K.;Zhang X.;Park S.R.;Fujii M.;Kang Y.-K.;Chen L.-T.; Shen L.; Shan Y.-S.; Hu H.-M.; Price T.J.; Sirohi B.; KUN-HUEI YEH; Yang Y.-H.; Sano T.; Yang H.-K.; Zhang X.; Park S.R.; Fujii M.; Kang Y.-K.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:00Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; HSIU-PO WANG; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; Cheng A.-L.; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 國立成功大學 |
2021 |
Comparing the clinicopathological characteristics of combined hepatocellular–cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification
|
Yen, C.-C.;Yen, C.-J.;Shan, Y.-S.;Lin, Y.-J.;Liu, I.-T.;Huang, Huang H.-Y.;Yeh, M.M.;Chan, S.-H.;Tsai, H.-W. |
| 國立成功大學 |
2021 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol
|
Shan, Y.-S.;Chen, L.-T.;Wu, C.-H.;Chang, Y.-F.;Lee, C.-T.;Chiang, N.-J.;Chao, Y.-J.;Yen, C.-J.;Tsai, H.-J.;Huang, Huang H.-E.;Tsai, C.-R.;Weng, Y.-L.;Yang, H.-C.;Liu, H.-C.;Chang, J.S. |
| 國立成功大學 |
2021 |
High expression of kr�ppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial
|
Pen, S.-L.;Shan, Y.-S.;Hsiao, C.-F.;Liu, T.-W.;Chen, J.-S.;Ho, C.-L.;Chou, W.-C.;Hsieh, R.-K.;Chen, L.-T.;Ch'ang, H.-J. |
| 國立成功大學 |
2021 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu, Hu H.-M.;Tsai, H.-J.;Ku, H.-Y.;Lo, S.-S.;Shan, Y.-S.;Chang, H.-C.;Chao, Y.;Chen, J.-S.;Chen, S.-C.;Chiang, Chiang C.-J.;Li, A.F.-Y.;Wang, H.-P.;Wang, T.-E.;Bai, L.-Y.;Wu, M.-S.;Chen, L.-T.;Liu, T.-W.;Yang, Yang Y.-H. |
| 國立成功大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, T.-J.;Su, Y.-Y.;Yang, S.-H.;Li, C.-P.;Bai, L.-Y.;Chiang, N.-J.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
顯示項目 36-45 / 95 (共10頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
